Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
2.320
+0.130 (5.98%)
Nov 7, 2024, 3:29 PM EST - Market open

Company Description

Lexaria Bioscience Corp. operates as a biotechnology company.

It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.

The company’s DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids.

Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods.

Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Lexaria Bioscience Corp.
Lexaria Bioscience logo
Country Canada
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Richard Christopher

Contact Details

Address:
740 McCurdy Road, Suite 100
Kelowna, BC V1X 2P7
Canada
Phone 250 765 6424
Website lexariabioscience.com

Stock Details

Ticker Symbol LEXX
Exchange NASDAQ
Fiscal Year September - August
Reporting Currency USD
CIK Code 0001348362
CUSIP Number 52886N406
ISIN Number US52886N4060
Employer ID 20-2000871
SIC Code 2834

Key Executives

Name Position
Richard C. Christopher Chief Executive Officer
John M. Docherty M.Sc. President and Director
Michael Shankman CPA Chief Financial Officer
Kristin Hamilton Director of Operations
Vanessa Carle Head of Legal

Latest SEC Filings

Date Type Title
Oct 18, 2024 8-K Current Report
Oct 16, 2024 8-K Current Report
Oct 16, 2024 D Notice of Exempt Offering of Securities
Oct 16, 2024 424B5 Filing
Oct 2, 2024 8-K Current Report
Sep 23, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 5, 2024 8-K Current Report
Aug 22, 2024 8-K Current Report
Aug 21, 2024 424B5 Filing
Aug 6, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership